ArticleFrontiers in medicine2026
Muscular involvement in Sjögren's disease is associated with male gender, Ro52 autoantibodies, and a higher clinical activity.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Sjögren's disease (SjD) is a systemic autoimmune disease that primarily affects exocrine glands. It can be associated with a variety of systemic manifestations, including myositis. At present, data evaluating muscular inflammation in SjD is limited, and further investigation is required. Methods: Patients with SjD and European Alliance of Associations for Rheumatology (EULAR) Sjögren's syndrome disease activity index (ESSDAI) muscular involvement (EMI) of at least six points in the muscular domain were recruited retrospectively from Hannover Medical School's SjD cohort after muscular inflammation was ascertained. Patients with SjD and EMI were characterised and compared with age- and sex-matched controls and with the entire SjD cohort. Results: A total of 26 of 492 SjD patients (5%) were diagnosed with EMI. The mean age of EMI onset was 56.4 years, the ratio between males and females was 12:14. Compared to SjD patients without EMI, SjD patients with EMI showed higher frequencies of Sjögren's Syndrome-related Antigen A/Ro(52) [SSA/Ro(52)] antibodies ( Conclusion: EMI is a rare but severe manifestation of SjD, occurring simultaneously with sicca symptoms. Male sex, positive SSA/Ro(52) antibodies, and high disease activity are more common in SjD patients with inflammatory myositis compared to those without muscular involvement.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.